Wu Audrey H, Parsons Lori, Every Nathan R, Bates Eric R
Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
J Am Coll Cardiol. 2002 Oct 16;40(8):1389-94. doi: 10.1016/s0735-1097(02)02173-3.
The purpose of this study was to examine treatment and outcomes in patients admitted to the hospital with acute myocardial infarction (AMI) complicated by congestive heart failure (CHF).
Although cardiogenic shock complicating AMI has been studied extensively, the hospital course of patients presenting with CHF is less well established.
The Second National Registry of Myocardial Infarction (NRMI-2) was analyzed to determine hospital outcomes for patients with ST-elevation AMI admitted with CHF (Killip classes II or III).
Of 190,518 patients with AMI, 36,303 (19.1%) had CHF on admission. Patients presenting with CHF were older (72.6 +/- 12.5 vs. 63.2 +/- 13.5 years), more often female (46.8% vs. 32.1%), had longer time to hospital presentation (2.80 +/- 2.6 vs. 2.50 +/- 2.4 h), and had higher prevalence of anterior/septal AMI (38.8% vs. 33.3%), diabetes (33.1% vs. 19.5%), and hypertension (54.6% vs. 46.1%) (all p < 0.0005). Also, they had longer lengths of stay (8.1 +/- 7.1 vs. 6.8 +/- 5.3 days, p < 0.00005) and greater risk for in-hospital death (21.4% vs. 7.2%; p < 0.0005). Patients with CHF were less likely to receive aspirin (75.7% vs. 89.0%), heparin (74.6% vs. 91.1%), oral beta-blockers (27.0% vs. 41.7%), fibrinolytics (33.4% vs. 58.0%), or primary angioplasty (8.6% vs. 14.6%), and more likely to receive angiotensin-converting enzyme inhibitors (25.4% vs. 13.0%). Congestive heart failure on admission was one of the strongest predictors of in-hospital death (adjusted odds ratio 1.68; 95% confidence interval 1.62, 1.75).
Patients with AMI presenting with CHF are at higher risk for adverse in-hospital outcomes. Despite this, they are less likely to be treated with reperfusion therapy and medications with proven mortality benefit.
本研究旨在探讨因急性心肌梗死(AMI)并发充血性心力衰竭(CHF)而入院患者的治疗情况及预后。
尽管对并发AMI的心源性休克已进行了广泛研究,但CHF患者的住院病程尚不明确。
分析第二次全国心肌梗死注册研究(NRMI - 2),以确定因CHF(Killip分级II或III级)入院的ST段抬高型AMI患者的住院结局。
在190,518例AMI患者中,36,303例(19.1%)入院时并发CHF。并发CHF的患者年龄更大(72.6±12.5岁对63.2±13.5岁),女性更多(46.8%对32.1%),到院就诊时间更长(2.80±2.6小时对2.50±2.4小时),前壁/前间隔AMI、糖尿病、高血压的患病率更高(38.8%对33.3%、33.1%对19.5%、54.6%对46.1%)(均p<0.0005)。此外,他们的住院时间更长(8.1±7.1天对6.8±5.3天,p<0.00005),院内死亡风险更高(21.4%对7.2%;p<0.0005)。并发CHF的患者接受阿司匹林、肝素、口服β受体阻滞剂、纤维蛋白溶解剂或直接血管成形术治疗的可能性较小(75.7%对89.0%、74.6%对91.1%、27.0%对41.7%、33.4%对58.0%、8.6%对14.6%),而接受血管紧张素转换酶抑制剂治疗的可能性较大(25.4%对13.0%)。入院时并发充血性心力衰竭是院内死亡的最强预测因素之一(校正比值比1.68;95%置信区间1.62, 1.75)。
因AMI并发CHF的患者发生不良院内结局的风险更高。尽管如此,他们接受有已证实的降低死亡率益处再灌注治疗和药物治疗的可能性较小。